Cetylev is a drug owned by Arbor Pharmaceuticals Llc. It is protected by 3 US drug patents filed from 2016 to 2017 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 08, 2032. Details of Cetylev's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9561204 | Effervescent compositions containing N-acetylcysteine |
May, 2032
(7 years from now) | Active |
| US8747894 | Effervescent compositions containing N-acetylcysteine |
May, 2032
(7 years from now) | Active |
| US9427421 | Effervescent compositions containing N-acetylcysteine |
May, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cetylev's patents.
Latest Legal Activities on Cetylev's Patents
Given below is the list of recent legal activities going on the following patents of Cetylev.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Jul, 2020 | US9561204 |
| Recordation of Patent Grant Mailed Critical | 07 Feb, 2017 | US9561204 |
| Patent Issue Date Used in PTA Calculation Critical | 07 Feb, 2017 | US9561204 |
| Email Notification Critical | 04 Feb, 2017 | US9561204 |
| Mail-Petition Decision - Granted | 01 Feb, 2017 | US9561204 |
| Petition Decision - Granted Critical | 31 Jan, 2017 | US9561204 |
| Email Notification Critical | 19 Jan, 2017 | US9561204 |
| Issue Notification Mailed Critical | 18 Jan, 2017 | US9561204 |
| Dispatch to FDC | 29 Dec, 2016 | US9561204 |
| Application Is Considered Ready for Issue Critical | 29 Dec, 2016 | US9561204 |
US patents provide insights into the exclusivity only within the United States, but Cetylev is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cetylev's family patents as well as insights into ongoing legal events on those patents.
Cetylev's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cetylev's generic launch date based on the expiry of its last outstanding patent is estimated to be May 08, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cetylev Generic API suppliers:
Acetylcysteine is the generic name for the brand Cetylev. 16 different companies have already filed for the generic of Cetylev, with Roxane having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cetylev's generic
Alternative Brands for Cetylev
Cetylev which is used for treating acetaminophen overdose., has several other brand drugs in the same treatment category and using the same active ingredient (Acetylcysteine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Cumberland Pharms |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Acetylcysteine, Cetylev's active ingredient. Check the complete list of approved generic manufacturers for Cetylev
About Cetylev
Cetylev is a drug owned by Arbor Pharmaceuticals Llc. It is used for treating acetaminophen overdose. Cetylev uses Acetylcysteine as an active ingredient. Cetylev was launched by Arbor Pharms Llc in 2016.
Approval Date:
Cetylev was approved by FDA for market use on 29 January, 2016.
Active Ingredient:
Cetylev uses Acetylcysteine as the active ingredient. Check out other Drugs and Companies using Acetylcysteine ingredient
Treatment:
Cetylev is used for treating acetaminophen overdose.
Dosage:
Cetylev is available in tablet, effervescent form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG | TABLET, EFFERVESCENT | Discontinued | ORAL |
| 2.5GM | TABLET, EFFERVESCENT | Discontinued | ORAL |